These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6073947)

  • 41. Christmas factor concentrates. The clinical use of several preparations.
    Tullis JL; Breen FA
    Bibl Haematol; 1970; 34():40-51. PubMed ID: 5436352
    [No Abstract]   [Full Text] [Related]  

  • 42. A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism.
    Yaish H; Rodgers GM
    Haemophilia; 2008 May; 14(3):607-9. PubMed ID: 18194306
    [No Abstract]   [Full Text] [Related]  

  • 43. Inhibitor development in haemophilia B: an orphan disease in need of attention.
    DiMichele D
    Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
    Curry NS; Misbah SA; Giangrande PL; Keeling DM
    Haemophilia; 2007 May; 13(3):328-30. PubMed ID: 17498084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
    Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
    Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor.
    Soto I; Vicente JM; Corte JR; Urgellés MF; Pinto CR
    Haemophilia; 2004 Jul; 10(4):401-4. PubMed ID: 15230957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

  • 49. [New formulation of recombinant coagulation factor: simplicity, rapidity and manageability].
    Fabregas B
    Soins; 2008 May; (725):22-3. PubMed ID: 18630084
    [No Abstract]   [Full Text] [Related]  

  • 50. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
    Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C
    J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Current treatment of hemophilia B].
    Tusell JM
    Sangre (Barc); 1997 Oct; 42(5):401-6. PubMed ID: 9424742
    [No Abstract]   [Full Text] [Related]  

  • 53. [Teeth extractions in 35 patients with hemophilia].
    Zhou SM; Gi LX; Yang TY
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1994 Sep; 29(5):291-3. PubMed ID: 7743865
    [No Abstract]   [Full Text] [Related]  

  • 54. How we treat: haematuria in adults with haemophilia.
    Quon DV; Konkle BA
    Haemophilia; 2010 Jul; 16(4):683-5. PubMed ID: 20041958
    [No Abstract]   [Full Text] [Related]  

  • 55. [The situation of hemophiliacs in Sweden].
    Nilsson IM
    Lakartidningen; 1981 Dec; 78(52):4725-8. PubMed ID: 6799720
    [No Abstract]   [Full Text] [Related]  

  • 56. Antibodies to factor IX.
    Warrier I
    Haematologica; 2000 Oct; 85(10 Suppl):31-3; discussion 33-4. PubMed ID: 11187867
    [No Abstract]   [Full Text] [Related]  

  • 57. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple extractions in hemophilia B--use of a PTC (factor IX) concentrate: report of case.
    Kline SN; Lewis JH; Bayer WL; Kahn MR
    J Oral Surg; 1970 Apr; 28(4):292-4. PubMed ID: 5309178
    [No Abstract]   [Full Text] [Related]  

  • 59. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
    Najaf SM; Malik A; Quraishi AU; Kazmi K; Kakepoto GN
    Ann Hematol; 2004 Sep; 83(9):604-7. PubMed ID: 15205916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E; Mauser-Bunschoten EP
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.